The deal will help iMetabolic speed development of therapeutic candidate molecules through its iPlatform technology for its peptide modulated fusion protein drug pipeline, it said. The molecules discovered on iPlatform using OmniAb are selectively engineered to improve target pathogen binding, and to elicit specific biological function for enhanced efficacy, clearance, and administration. Specifically, the technology will be used to advance iMetabolic's lead product, iMBP-001. OmniAb is an antigen production platform consisting of the following transgenic animals: OmniRat, OmniMouse, OmniFlic, OmniClic, OmniTaur, and OmniChicken.

AbbVie licenses anti-COVID-19 antibody for clinical development
Harbour BioMed and Utrecht University have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie. AbbVie has initiated a phase...

Inovio to develop COVID-19 DNA-encoded monoclonal antibodies
Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a...

Eureka touts preclinical results for COVID-19 antibody nasal spray
Eureka Therapeutics has touted positive preclinical results for its InvisiMask antibody nasal spray.

Alligator launches new human antibody library
Alligator Bioscience has launched a new human antibody library in fragment antigen-binding format.

New study finds SARS-CoV-2 antibodies disappear quickly
Antibodies that develop after infection with the SARS-CoV-2 virus disappear quickly, according to an analysis published in Science Immunology...